Related Experiment Videos
[Ticlopidine-induced acute cholestatic hepatitis. A case report]
Alberto Gandolfi1, Marco Mengoli, Edda Rota
1Divisione di Medicina Interna, Ospedale San Sebastiano, Correggio, ASL di Reggio Emilia.
Recenti Progressi in Medicina
|April 10, 2004
Summary
A 72-year-old man developed acute cholestatic hepatitis after taking the antiplatelet drug ticlopidine. Liver function normalized after discontinuing ticlopidine, suggesting drug-induced liver injury.
Area of Science:
- Hepatology
- Clinical Pharmacology
Background:
- Ticlopidine is an antiplatelet agent used to prevent thrombotic events.
- Coronary angioplasty and stent implantation are procedures often requiring antiplatelet therapy.
Observation:
- A 72-year-old male patient developed acute cholestatic hepatitis.
- Hepatitis onset occurred three weeks after initiating ticlopidine therapy post-coronary angioplasty and stent implantation for unstable angina.
Findings:
- A strong temporal association was observed between ticlopidine administration and the acute onset of liver damage.
- Other causes of hepatobiliary disease were excluded.
- Biochemical liver parameters progressively normalized after ticlopidine withdrawal.
Implications:
- Ticlopidine may be implicated in the pathogenesis of drug-induced liver injury, specifically cholestatic hepatitis.
- Clinicians should consider ticlopidine as a potential cause of hepatitis in patients presenting with liver dysfunction.
- Monitoring liver function is crucial in patients receiving ticlopidine, especially those with cardiovascular conditions.